78 related articles for article (PubMed ID: 19307998)
1. Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer.
Neninger E; Verdecia BG; Crombet T; Viada C; Pereda S; Leonard I; Mazorra Z; Fleites G; González M; Wilkinson B; González G; Lage A
J Immunother; 2009 Jan; 32(1):92-9. PubMed ID: 19307998
[TBL] [Abstract][Full Text] [Related]
2. Pilot study of a novel combination of two therapeutic vaccines in advanced non-small-cell lung cancer patients.
Herrera ZM; Ramos TC
Cancer Immunol Immunother; 2014 Jul; 63(7):737-47. PubMed ID: 24777612
[TBL] [Abstract][Full Text] [Related]
3. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy.
Rodríguez PC; Rodríguez G; González G; Lage A
MEDICC Rev; 2010; 12(1):17-23. PubMed ID: 20387330
[TBL] [Abstract][Full Text] [Related]
4. CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer.
Crombet Ramos T; Rodríguez PC; Neninger Vinageras E; Garcia Verdecia B; Lage Davila A
Expert Rev Vaccines; 2015; 14(10):1303-11. PubMed ID: 26295963
[TBL] [Abstract][Full Text] [Related]
5. CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine.
Tagliamento M; Rijavec E; Barletta G; Biello F; Rossi G; Grossi F; Genova C
Expert Opin Biol Ther; 2018 Jul; 18(7):829-835. PubMed ID: 29936901
[TBL] [Abstract][Full Text] [Related]
6. Safety and effectiveness of CIMAvax-EGF administered in community polyclinics.
Ortiz Carrodeguas RA; Lorenzo Monteagudo G; Guerra Chaviano PP; Álvarez Montané I; Salomón Saldívar EE; Lobaina Lambert L; Camacho Sosa K; Bermúdez Pino R; Blanco Mustelier P; Valdés Rodríguez E; González Piloto S; Guerra de la Vega A; Valdés Sánchez L; Montes De Santis A; Parra Zabala J; Viada González C; Calvo Aguilera N; Saavedra Hernández D; Santos Morales O; Crombet Ramos T
Front Oncol; 2023; 13():1287902. PubMed ID: 38304035
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in neoantigen vaccines for treating non-small cell lung cancer.
Su S; Chen F; Xu M; Liu B; Wang L
Thorac Cancer; 2023 Dec; 14(34):3361-3368. PubMed ID: 37905603
[TBL] [Abstract][Full Text] [Related]
8. Advances in the Lung Cancer Immunotherapy Approaches.
Padinharayil H; Alappat RR; Joy LM; Anilkumar KV; Wilson CM; George A; Valsala Gopalakrishnan A; Madhyastha H; Ramesh T; Sathiyamoorthi E; Lee J; Ganesan R
Vaccines (Basel); 2022 Nov; 10(11):. PubMed ID: 36423060
[TBL] [Abstract][Full Text] [Related]
9. Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule.
Popa X; García B; Fuentes KP; Huerta V; Alvarez K; Viada CE; Neninger E; Rodríguez PC; González Z; González A; Crombet T; Mazorra Z
Oncoimmunology; 2020 May; 9(1):1762465. PubMed ID: 32923124
[TBL] [Abstract][Full Text] [Related]
10. Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study-A Brief Research Report.
Kjeldsen JW; Iversen TZ; Engell-Noerregaard L; Mellemgaard A; Andersen MH; Svane IM
Front Immunol; 2018; 9():2145. PubMed ID: 30283461
[No Abstract] [Full Text] [Related]
11. Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles.
Cho JH
Immune Netw; 2017 Dec; 17(6):378-391. PubMed ID: 29302251
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
13. Current state of immunotherapy for non-small cell lung cancer.
Malhotra J; Jabbour SK; Aisner J
Transl Lung Cancer Res; 2017 Apr; 6(2):196-211. PubMed ID: 28529902
[TBL] [Abstract][Full Text] [Related]
14. CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients.
Saavedra D; Crombet T
Front Immunol; 2017; 8():269. PubMed ID: 28348561
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting.
Mountzios G; Linardou H; Kosmidis P
Ann Transl Med; 2016 Jul; 4(14):268. PubMed ID: 27563655
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of immunotherapy in patients with advanced NSCLC: a systematic review and meta-analysis.
Zhou L; Wang XL; Deng QL; Du YQ; Zhao NQ
Sci Rep; 2016 Aug; 6():32020. PubMed ID: 27558285
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of pluripotent cell-engineered vaccines and their potential to treat lung cancer in relation to different levels of irradiation.
Zhang YN; Duan XG; Zhang WH; Wu AL; Yang HH; Wu DM; Wei YQ; Chen XC
Onco Targets Ther; 2016; 9():1425-36. PubMed ID: 27042111
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticle delivery of CDDO-Me remodels the tumor microenvironment and enhances vaccine therapy for melanoma.
Zhao Y; Huo M; Xu Z; Wang Y; Huang L
Biomaterials; 2015 Nov; 68():54-66. PubMed ID: 26264646
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
